Paret K, Beyhaghi H, Herring W, Rousculp M, Toback S, Mauskopf J. Assessing the cost-effectiveness of the Novavax COVID-19 vaccine as a potential booster vaccine option for adults in the United States. Poster presented at the ISPOR Europe 2022; November 7, 2022. Vienna, Austria. [abstract] Value Health. 2022 Dec 1; 25(12):S89. doi: 10.1016/j.jval.2022.09.434
Paret K, Beyhaghi H, Herring W, Rousculp M, Toback S, Mauskopf J. Population-level model of the health and economic impact of NVX-CoV2373 as a COVID-19 booster vaccine option for adults in the United States. Poster presented at the Society for Medical Decision Making (SMDM) 44th Annual North American Meeting; October 25, 2022. Seattle, WA.